Literature DB >> 1609280

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.

P N Fultz1, P Nara, F Barre-Sinoussi, A Chaput, M L Greenberg, E Muchmore, M P Kieny, M Girard.   

Abstract

Because human immunodeficiency virus (HIV) can be transmitted as cell-free virus or as infected cells (cell-associated virus), vaccines must protect against infection by both viral forms. Vaccine-mediated protection of nonhuman primates against low doses of cell-free HIV-1, HIV-2, or simian immunodeficiency virus (SIV) has been demonstrated. It is now shown that multiple immunizations of chimpanzees with HIV-1 antigens protected against infection with cell-associated virus. Protection can persist for extended periods (one animal had not been exposed to viral antigens for 1 year before challenge). These results show that it is possible to elicit long-lasting protective immunity against cell-associated HIV-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1609280     DOI: 10.1126/science.256.5064.1687

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  33 in total

1.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.

Authors:  Jason L Dehart; Vicente Planelles
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 5.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

6.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

Authors:  Z R Israel; P F Edmonson; D H Maul; S P O'Neil; S P Mossman; C Thiriart; L Fabry; O Van Opstal; C Bruck; F Bex
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry.

Authors:  A B Sabin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.